West Nile Virus Antibody, IgM by ELISA, CSF
Also known as: WNIL IGM
Use
This test is intended for the semi-quantitative detection of West Nile virus-specific IgM in cerebrospinal fluid (CSF) specimens where there is clinical suspicion of West Nile virus infection. The presence of IgM antibodies may indicate a current or recent infection with the virus. However, consideration must be given to potential cross-reactivity with other viruses in the Flaviviridae family (such as St. Louis encephalitis virus), contamination by blood, or transfer of serum antibodies across the blood-brain barrier.
Special Instructions
Not provided.
Limitations
The test is developed by ARUP Laboratories as an LDT and has not been cleared or approved by the FDA. Cross-reactivity with other members of the Flaviviridae family might occur, and serologic testing specific to these species should be considered. A false positive rate of 2-3% has been demonstrated with the Focus Diagnostics ELISA assay. It's important to repeat testing in 10-14 days if the results are equivocal.
Methodology
Immunoassay (ELISA)
Biomarkers
West Nile Virus IgM Antibody
Protein
LOINC Codes
- 39573-1 - WNV IgM CSF IA-aCnc
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated. New York State Clients: Frozen
Causes for Rejection
Bacterially contaminated, heat-inactivated, hemolyzed or xanthochromic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |
Other tests from different labs that may be relevant